NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NVCR
- CUSIP: N/A
- Web: www.novocure.com
Capitalization:- Market Cap: $1.7133 billion
- Outstanding Shares: 89,002,000
Average Prices:- 50 Day Moving Avg: $18.94
- 200 Day Moving Avg: $12.66
- 52 Week Range: $5.95 - $21.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -44.88
- P/E Growth: -0.43
Sales & Book Value:- Annual Revenue: $125.17 million
- Price / Sales: 13.40
- Book Value: $1.33 per share
- Price / Book: 14.17
Profitability:- EBIDTA: ($69,140,000.00)
- Net Margins: -75.91%
- Return on Equity: -69.48%
- Return on Assets: -34.71%
Debt:- Debt-to-Equity Ratio: 0.82%
- Current Ratio: 6.72%
- Quick Ratio: 6.01%
Misc:- Average Volume: 965,116 shs.
- Beta: 4.43
- Short Ratio: 7.48
Frequently Asked Questions for NovoCure Limited (NASDAQ:NVCR)
What is NovoCure Limited's stock symbol?
NovoCure Limited trades on the NASDAQ under the ticker symbol "NVCR."
How were NovoCure Limited's earnings last quarter?
NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, July, 27th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The firm earned $38.38 million during the quarter, compared to analysts' expectations of $42.20 million. NovoCure Limited had a negative return on equity of 69.48% and a negative net margin of 75.91%. View NovoCure Limited's Earnings History.
When will NovoCure Limited make its next earnings announcement?
Where is NovoCure Limited's stock going? Where will NovoCure Limited's stock price be in 2017?
6 analysts have issued 12 month target prices for NovoCure Limited's shares. Their predictions range from $14.00 to $34.00. On average, they anticipate NovoCure Limited's stock price to reach $19.33 in the next year. View Analyst Ratings for NovoCure Limited.
What are analysts saying about NovoCure Limited stock?
Here are some recent quotes from research analysts about NovoCure Limited stock:
- 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (8/1/2017)
- 2. J P Morgan Chase & Co analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)
Who are some of NovoCure Limited's key competitors?
Some companies that are related to NovoCure Limited include Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS) and Lexicon Pharmaceuticals (LXRX).
Who are NovoCure Limited's key executives?
NovoCure Limited's management team includes the folowing people:
- William F. Doyle, Executive Chairman of the Board
- Asaf Danziger, Chief Executive Officer, Director
- Kinyip Gabriel Leung, Vice Chairman of the Board
- Yoram Palti M.D., Ph.D., Founder, Director
- Wilhelmus C. M. Groenhuysen, Chief Financial Officer
- Michael J. Ambrogi, Chief Operating Officer
- Eilon D. Kirson M.D., Ph.D., Chief Science Officer and Head of Research and Development
- Todd Longsworth, General Counsel
- William T. Burkoth, Independent Director
- Louis J. Lavigne Jr., Independent Director
Who owns NovoCure Limited stock?
NovoCure Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (7.74%), Goldman Sachs Group Inc. (5.60%), Vanguard Group Inc. (4.81%), StepStone Group LP (2.04%), State Street Corp (1.22%) and Peregrine Capital Management LLC (0.96%). Company insiders that own NovoCure Limited stock include Asaf Danziger, Eilon D Kirson, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Robert J Mylod Jr and Yoram Palti. View Institutional Ownership Trends for NovoCure Limited.
Who sold NovoCure Limited stock? Who is selling NovoCure Limited stock?
NovoCure Limited's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Macquarie Group Ltd., Wedbush Securities Inc., ProShare Advisors LLC and SG Americas Securities LLC. Company insiders that have sold NovoCure Limited stock in the last year include Asaf Danziger, Eilon D Kirson, Michael J Ambrogi, Pomona Capital Vii Fund Invest and Yoram Palti. View Insider Buying and Selling for NovoCure Limited.
Who bought NovoCure Limited stock? Who is buying NovoCure Limited stock?
NovoCure Limited's stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., FMR LLC, Vanguard Group Inc., Frontier Capital Management Co. LLC, PointState Capital LP, C WorldWide Group Holding A S, State Street Corp and Engineers Gate Manager LP. Company insiders that have bought NovoCure Limited stock in the last two years include Asaf Danziger, Gert L Perlhagen and Robert J Mylod Jr. View Insider Buying and Selling for NovoCure Limited.
How do I buy NovoCure Limited stock?
Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovoCure Limited's stock price today?
One share of NovoCure Limited stock can currently be purchased for approximately $18.85.
MarketBeat Community Rating for NovoCure Limited (NASDAQ NVCR)MarketBeat's community ratings are surveys of what our community members think about NovoCure Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for NovoCure Limited (NASDAQ:NVCR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $19.33 (2.56% upside) |
Analysts' Ratings History for NovoCure Limited (NASDAQ:NVCR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $18.00 -> $19.00 | Low |  |
| 5/24/2017 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | $15.00 | High | |
| 5/1/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | $14.00 | High | |
| 4/27/2017 | Wedbush | Reiterated Rating | Outperform | $20.00 | Low | |
| 4/18/2017 | Aegis | Reiterated Rating | Buy | $14.00 | Low | |
| 4/4/2017 | JMP Securities | Reiterated Rating | Outperform | $34.00 | High | |
| 7/29/2016 | Barclays PLC | Lower Price Target | Underweight | $12.00 -> $9.00 | N/A | |
| 11/12/2015 | Evercore ISI | Initiated Coverage | Buy | $29.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for NovoCure Limited (NASDAQ:NVCR)Earnings History by Quarter for NovoCure Limited (NASDAQ NVCR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.15) | | | | | N/A | |
| 7/27/2017 | 6/30/2017 | ($0.23) | ($0.24) | $42.20 million | $38.38 million | View | N/A | |
| 4/27/2017 | 3/31/2017 | ($0.25) | ($0.21) | $39.46 million | $34.88 million | View | N/A | |
| 2/23/2017 | Q416 | ($0.39) | ($0.26) | $26.95 million | $30.20 million | View | N/A | |
| 11/2/2016 | Q3 2016 | ($0.42) | ($0.39) | $21.65 million | $21.67 million | View | N/A | |
| 7/28/2016 | Q216 | ($0.37) | ($0.48) | $15.90 million | $17.90 million | View | Listen | |
| 5/9/2016 | Q116 | ($0.33) | ($0.42) | $23.65 million | $13.10 million | View | N/A | |
| 10/26/2015 | Q315 | | ($2.09) | $4.37 million | $8.95 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for NovoCure Limited (NASDAQ:NVCR)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q3 2017 | 1 | ($0.25) | ($0.25) | ($0.25) |
| Q4 2017 | 1 | ($0.25) | ($0.25) | ($0.25) |
(Data provided by Zacks Investment Research)
Dividend History for NovoCure Limited (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NovoCure Limited (NASDAQ:NVCR)Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 25.15%
Insider Trades by Quarter for NovoCure Limited (NASDAQ:NVCR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/11/2017 | Asaf Danziger | CEO | Sell | 7,383 | $19.95 | $147,290.85 | |
| 7/10/2017 | Asaf Danziger | CEO | Sell | 274,359 | $18.07 | $4,957,667.13 | |
| 7/6/2017 | Asaf Danziger | CEO | Sell | 160,138 | $18.14 | $2,904,903.32 | |
| 7/5/2017 | Asaf Danziger | CEO | Sell | 155,088 | $18.14 | $2,813,296.32 | |
| 6/26/2017 | Pomona Capital Vii Fund Invest | Major Shareholder | Sell | 1,072,532 | $17.35 | $18,608,430.20 | |
| 6/21/2017 | Eilon D Kirson | Insider | Sell | 66,361 | $16.78 | $1,113,537.58 | |
| 6/19/2017 | Asaf Danziger | CEO | Sell | 124,720 | $15.51 | $1,934,407.20 | |
| 6/19/2017 | Eilon D Kirson | Insider | Sell | 15,000 | $15.06 | $225,900.00 | |
| 6/16/2017 | Asaf Danziger | CEO | Sell | 42,457 | $15.15 | $643,223.55 | |
| 6/14/2017 | Asaf Danziger | CEO | Sell | 94,102 | $15.22 | $1,432,232.44 | |
| 6/12/2017 | Asaf Danziger | CEO | Sell | 180,601 | $15.13 | $2,732,493.13 | |
| 6/12/2017 | Eilon D Kirson | Insider | Sell | 20,956 | $15.03 | $314,968.68 | |
| 6/5/2017 | Yoram Palti | Insider | Sell | 3,825 | $13.82 | $52,861.50 | |
| 6/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $13.27 | $106,160.00 | |
| 5/31/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.49 | $99,920.00 | |
| 5/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.88 | $103,040.00 | |
| 5/24/2017 | Yoram Palti | Insider | Sell | 4,000 | $13.15 | $52,600.00 | |
| 5/23/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.73 | $93,840.00 | |
| 5/19/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.39 | $91,120.00 | |
| 5/17/2017 | Yoram Palti | Insider | Sell | 4,000 | $11.47 | $45,880.00 | |
| 5/16/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.05 | $96,400.00 | |
| 5/12/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.79 | $94,320.00 | |
| 5/10/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.29 | $98,320.00 | |
| 5/8/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.82 | $94,560.00 | |
| 5/4/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.42 | $91,360.00 | |
| 5/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.64 | $93,120.00 | |
| 4/28/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.25 | $90,000.00 | |
| 4/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $10.78 | $86,240.00 | |
| 4/24/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.26 | $90,080.00 | |
| 4/20/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.24 | $89,920.00 | |
| 4/18/2017 | Yoram Palti | Insider | Sell | 16,000 | $10.64 | $170,240.00 | |
| 4/17/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.77 | $43,080.00 | |
| 4/13/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.43 | $41,720.00 | |
| 4/12/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.72 | $42,880.00 | |
| 3/14/2017 | Gert L Perlhagen | Director | Buy | 125,000 | $6.93 | $866,250.00 | |
| 12/22/2016 | Michael J Ambrogi | COO | Sell | 27,500 | $8.27 | $227,425.00 | |
| 12/20/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.62 | $172,400.00 | |
| 12/19/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.76 | $175,200.00 | |
| 12/16/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.93 | $357,200.00 | |
| 12/14/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.97 | $358,800.00 | |
| 12/12/2016 | Michael J Ambrogi | COO | Sell | 15,000 | $9.01 | $135,150.00 | |
| 12/8/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.30 | $83,000.00 | |
| 12/6/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.24 | $82,400.00 | |
| 8/5/2016 | Gert L Perlhagen | Director | Sell | 676,576 | $1.85 | $1,251,665.60 | |
| 6/8/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $12.24 | $244,800.00 | |
| 3/3/2016 | Asaf Danziger | CEO | Buy | 10,000 | $15.00 | $150,000.00 | |
| 3/3/2016 | Robert J Mylod Jr | Director | Buy | 20,000 | $15.78 | $315,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for NovoCure Limited (NASDAQ:NVCR)
Latest Headlines for NovoCure Limited (NASDAQ:NVCR)
| Source: |
|
| Date | Headline |
|---|
 | NovoCure Limited (NVCR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 11:56 AM |
 | ETFs with exposure to Novocure Ltd. : August 11, 2017
finance.yahoo.com - August 12 at 6:25 AM |
| ETFs with exposure to Novocure Ltd. : August 11, 2017
finance.yahoo.com - August 12 at 6:25 AM |
| Analysts Expect NovoCure Limited (NVCR) Will Post Quarterly Sales of $43.26 Million
www.americanbankingnews.com - August 11 at 4:04 PM |
 | 3 Earnings Movers Among Our 4 Charts To Watch
www.nasdaq.com - August 10 at 6:22 AM |
| Novocure™ Announces National Reimbursement for Optune® in Austria
finance.yahoo.com - August 9 at 5:35 AM |
| Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 3 at 6:28 AM |
| 3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
finance.yahoo.com - August 3 at 6:28 AM |
| Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
finance.yahoo.com - July 29 at 5:43 AM |
| Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - July 28 at 6:17 AM |
| Investor Network: Novocure Ltd. to Host Earnings Call
finance.yahoo.com - July 28 at 6:17 AM |
| Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 28 at 6:17 AM |
| NovoCure reports 2Q loss
finance.yahoo.com - July 28 at 6:17 AM |
| NovoCure Limited (NASDAQ:NVCR) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - July 27 at 2:18 PM |
| Commit To Buy NovoCure At $15, Earn 19.7% Annualized Using Options - Nasdaq
www.nasdaq.com - July 27 at 5:35 AM |
| Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma
finance.yahoo.com - July 24 at 8:57 AM |
| NovoCure Limited (NASDAQ:NVCR) Expected to Post Quarterly Sales of $42.20 Million
www.americanbankingnews.com - July 22 at 12:20 PM |
| Many treatment options, most experimental, available to John McCain
finance.yahoo.com - July 22 at 7:07 AM |
| NovoCure Limited (NVCR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 9:12 AM |
| Brokerages Anticipate NovoCure Limited (NVCR) to Announce -$0.21 EPS
www.americanbankingnews.com - July 20 at 9:15 AM |
| Novocure Ltd (NVCR) Price Target Raised to $19.00 at Deutsche Bank AG
www.americanbankingnews.com - July 17 at 7:14 PM |
 | Today's Research Report Coverage on Medical Equipment Stocks -- NovoCure, Corindus Vascular Robotics ... - PR Newswire (press release)
www.prnewswire.com - July 17 at 9:25 AM |
| NovoCure Limited (NVCR) CEO Asaf Danziger Sells 7,383 Shares
www.americanbankingnews.com - July 13 at 8:17 PM |
| NovoCure (NVCR) Jumps: Stock Rises 10.5% - Nasdaq
www.nasdaq.com - July 13 at 7:27 AM |
| Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.
finance.yahoo.com - July 13 at 7:27 AM |
| Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd.
finance.yahoo.com - July 13 at 7:27 AM |
| NovoCure (NVCR) Jumps: Stock Rises 10.5%
finance.yahoo.com - July 13 at 7:27 AM |
| The Fastest Growing Cancer Company You've Never Heard Of
finance.yahoo.com - July 13 at 7:27 AM |
| Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
finance.yahoo.com - July 12 at 6:29 AM |
| NovoCure Limited (NVCR) CEO Sells $4,957,667.13 in Stock
www.americanbankingnews.com - July 11 at 7:53 PM |
| NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger Sells 155,088 Shares
www.americanbankingnews.com - July 7 at 7:58 PM |
| Asaf Danziger Sells 160,138 Shares of NovoCure Limited (NVCR) Stock
www.americanbankingnews.com - July 7 at 7:56 PM |
| Zacks Investment Research Downgrades NovoCure Limited (NASDAQ:NVCR) to Sell
www.americanbankingnews.com - July 3 at 9:32 PM |
| NovoCure Limited (NASDAQ:NVCR) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 2 at 7:28 AM |
| Is NovoCure (NVCR) a Great Growth Stock? - Nasdaq
www.nasdaq.com - July 1 at 5:49 AM |
| Novocure to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 1 at 5:49 AM |
| Is NovoCure (NVCR) a Great Growth Stock?
finance.yahoo.com - July 1 at 5:49 AM |
| Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer
finance.yahoo.com - June 28 at 1:34 PM |
| NovoCure Limited (NVCR) Major Shareholder Sells $18,608,430.20 in Stock
www.americanbankingnews.com - June 27 at 7:28 PM |
| NovoCure Limited (NVCR) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 26 at 9:02 AM |
| $42.20 Million in Sales Expected for NovoCure Limited (NVCR) This Quarter
www.americanbankingnews.com - June 25 at 7:40 AM |
| Novocure Ltd (NVCR) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - June 23 at 10:20 PM |
| NovoCure Limited (NVCR) Insider Sells $1,113,537.58 in Stock
www.americanbankingnews.com - June 22 at 7:28 PM |
| NovoCure Limited (NVCR) Insider Eilon D. Kirson Sells 15,000 Shares
www.americanbankingnews.com - June 21 at 7:46 PM |
| NovoCure Limited (NVCR) CEO Sells $1,934,407.20 in Stock
www.americanbankingnews.com - June 21 at 7:24 PM |
| NovoCure Limited (NVCR) CEO Asaf Danziger Sells 42,457 Shares
www.americanbankingnews.com - June 19 at 7:20 PM |
| NovoCure Limited (NVCR) CEO Asaf Danziger Sells 94,102 Shares
www.americanbankingnews.com - June 15 at 7:22 PM |
| Insider Selling: NovoCure Limited (NVCR) Insider Sells 20,956 Shares of Stock
www.americanbankingnews.com - June 13 at 7:54 PM |
| NovoCure Limited (NVCR) CEO Asaf Danziger Sells 180,601 Shares
www.americanbankingnews.com - June 13 at 7:28 PM |
| Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
finance.yahoo.com - June 13 at 7:02 PM |
NovoCure Limited (NVCR) Chart for Saturday, August, 19, 2017
